A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 4 of the 19 sources its claims cite were checked for support.
Abstract
Background: In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and provide a multi-omic correlative analysis of actionable biomarkers. Methods: Patients were randomized (non-comparative) to receive either N or N+I. The primary endpoint was a 6-month confirmed response rate (CRR) defined by Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints included treatment-related adverse events (TRAEs), progression-free survival, and overall survival. Multi-omic correlative analyses were conducted using samples from both the primary and expansion cohorts. Results: A total of 66 patients were evaluated for the primary endpoint with disease including gastrointestinal stromal tumor (GIST, n=18), undifferentiated pleomorphic sarcoma (UPS, n=24), and dedifferentiated liposarcoma (DDLPS, n=24). Neither N nor N+I achieved a complete or partial response in the GIST expansion cohort. In DDLPS and UPS, the primary response endpoint of CRR was met with N+I (both 16.6%, 2/12) but not with N alone (both 8.3%, 1/12). In the GIST cohort, TRAE was higher with N+I treatment, halting enrollment as required per protocol. In a correlative analysis of patients for the expansion cohort and the original cohort (n=86), traditional biomarkers of immunotherapy response were not correlated with response in any histological subtype. Markers of genomic instability including the presence of gene fusions and increased subclonal mutations correlated with improved clinical outcomes. Conclusions: This expansion cohort reaffirms the outcomes of A091401. There remains a pressing need to determine the role of and predictive biomarkers for immunotherapy in sarcoma. Trial registration number: NCT02500797.
Overview
CoChat Summary
TL;DR
This phase II expansion of Alliance A091401 found confirmed activity of nivolumab plus ipilimumab, but not nivolumab alone, in dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS), while gastrointestinal stromal tumors (GIST) had no confirmed responses. Exploratory correlative analyses found no association for standard immune biomarkers, but did find signals for genomic instability markers, especially gene fusions and subclonal mutations.
Key findings
- In the expansion cohort, confirmed response rate (CRR) met the prespecified threshold for promise in DDLPS and UPS with nivolumab + ipilimumab: 2/12 (16.6%) in the primary analysis for each histology; nivolumab alone was 1/12 (8.3%) in each.
- In the full treated cohorts, CRR was 0% (0/10) for GIST with nivolumab and 0% (0/11) with nivolumab + ipilimumab; no confirmed responses occurred in GIST.
- Secondary endpoints showed median PFS/OS, respectively:
- DDLPS: nivolumab 4.6 months PFS, 8.1 months OS; nivolumab + ipilimumab 5.5 months PFS, 14.6 months OS.
- UPS: nivolumab 1.4 months PFS, 6.6 months OS; nivolumab + ipilimumab 2.7 months PFS, 15.2 months OS.
- GIST: nivolumab 1.5 months PFS, 9.1 months OS; nivolumab + ipilimumab 2.9 months PFS, 12.2 months OS.
- Among exploratory biomarkers, PD-L1 expression was not associated with response, TMB was low (median 1.7 Mut/Mb; high TMB >10 Mut/Mb in n=1), and no tumors were MSI-high; by contrast, presence of any gene fusion was associated with PFS ≥12 weeks (p=0.01) and longer PFS (HR 0.20, 95% CI 0.08–0.51, p<0.001) and OS (HR 0.29, 95% CI 0.12–0.71, p=0.006).
- In DDLPS, a higher proportion of subclonal mutations was associated with better outcomes: high subclonal fraction was linked to improved PFS (HR 0.27, 95% CI 0.09–0.83, p=0.003) and OS (HR 0.26, 95% CI 0.08–0.85, p=0.01).
Methods
- Multicenter, unblinded, randomized, non-comparative phase II expansion cohorts of GIST, DDLPS, and UPS; patients were assigned 1:1 to nivolumab or nivolumab + ipilimumab, and each treatment arm/tumor type was treated as an independent trial.
- Eligible patients were ≥18 years, had locally advanced/unresectable/metastatic disease, measurable disease by RECIST 1.1, ECOG 0–1, prior systemic therapy, and no prior anti-PD-1/PD-L1/CTLA-4 therapy; 79 patients registered and 77 started treatment.
- Primary endpoint was confirmed objective response rate (CRR); secondary endpoints were duration of response, clinical benefit rate, PFS, and OS. Exploratory correlative analyses used pretreatment tissue from 86 patients (with 82 evaluable after exclusions), including IHC, DNA sequencing, RNA-seq, fusion calling, TMB, clonality, and pathway analysis, with 12-week PFS as the screening correlative endpoint.
Limitations
- The paper states the study was not designed to make direct comparisons between nivolumab and nivolumab + ipilimumab, so any impression of greater activity for combination therapy is not statistically comparable.
- The correlative analysis was exploratory, and the authors note the low response rate limited power; they state further study is needed in larger cohorts.
- Evident from the text: sample sizes were small and uneven by histology, with only 30 tumors analyzed by RNA-seq and 86 total patients entering correlative analyses, which limits subtype-level inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
2 Valid · 1 Not valid · 11 Not checked · 102 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“TMB is not typically associated with response to ICI efficacy with the exception of rare, TMB-high sarcomas including pleomorphic dermal sarcoma and cutaneous angiosarcoma. 13”
What the sources say
- Partly supportedcites [13] D’Angelo, 2022, Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma, Nat Commun sourceExperimental — accuracy not yet measured
The Results ('Genomic features of sarcomas') support the general point: TMB (median 1.22 mut/Mb) 'was not significantly associated with ORR or PFS,' and the Discussion repeats that genomic markers such as TMB, neoantigen load and LOH did not correlate with clinical benefit. The exception clause is only partly covered: the Discussion states that elevated TMB with dominant UV-signature mutations 'have been found to be potential predictive biomarkers of benefit in cutaneous, head, and neck angiosarcomas' — hedged as 'potential' and credited to another work (reference 31), not this study's own finding, and it immediately adds that 3 of 8 patients with NON-cutaneous angiosarcoma benefited despite low TMB, so conventional genomic markers alone may not suffice. Pleomorphic dermal sarcoma is not mentioned anywhere in our copy (searched 'pleomorphic dermal sarcoma'; the paper only discusses undifferentiated pleomorphic sarcoma, UPS, in relation to FGA), so that member of the exception list is unsupported by this source. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Tumor mutational burden (TMB), a key indicator of ICI response in most tumors, is generally low across sarcoma subtypes.”
What the sources say
- Supportedcites [13] D’Angelo, 2022, Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma, Nat Commun source
The Introduction states that high TMB is low across most sarcoma subtypes. The Results (Genomic features of sarcomas) also report relatively low TMB in the study samples compared with other tumor types, supporting the claim’s 'generally low' wording. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we provide preliminary evidence for the potential of markers of genomic instability, including the presence of gene fusions and increased subclonal mutations, as correlated with response to immunotherapy in STS.”
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the over accrued patients experienced a confirmed response, leading to an overall CRR of 1/13 (7.7%) in the N arm and 2/14 (16.6%) in the N+I arm.”
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CRR for DDPLS was 8.3% (1/12) for N and 16.6% (2/12) for N+I.”
plainn = 12- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
55 more claims
Create a free account to see all 116 claims and to verify the 15 references still open.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 41
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“leading to an overall CRR of 1/13 (7.7%) in the N arm and 2/14 (16.6%) in the N+I arm.”
Reported 16.6 · recomputed 14.285714
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“In patients with UPS receiving N alone CBR was 28.6% versus 53.3% for N+I.”
“Finally, for the 27 UPS patients, 13 were randomized to N and 14 to N+I.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Four of the 86 patients were excluded from correlative analysis due to the lack of a reported PFS (n=2) or censoring of PFS before 12 weeks of treatment (n=2).”
“Patients included in this analysis were evenly distributed between N (n=41) and N+I (n=42) treatment arms.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Gene pathway expression was evaluated with GSEA 30 using the Hallmark gene sets 31 with a significance filtering of absolute normalized enrichment scores (NES) ≥1.5 and q<0.1.”
“For all molecular analysis, the false discovery rate was controlled with the Benjamini-Hochberg method using a threshold of q<0.05.”
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“Clonality was called by first calculating the cancer cell fraction of each mutation using ccf- annotate-maf in facets-suite 28 (https://github.com/mskcc/facets-suite).”
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Cited by
Wilky, B. A., Schwartz, G. K., Gordon, M. S., El-Khoueiry, A. B., Bullock, A. J., Henick, B. S., Agulnik, M., Singh, A. S., Mahadevan, D., Stebbing, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02524 · Cited by 31
Self-citationImmunotherapy in the Treatment of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma
Wu, J. T., Nowak, E., Imamura, J., Leng, J., Shepard, D. R., Campbell, S. R., Scott, J. G., Nystrom, L. M., Mesko, N. W., Schwartz, G. K., et al. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01349-x · Cited by 8
Self-citationMiwa, S., Yamamoto, N., Hayashi, K., Taniguchi, Y., Yonezawa, H., Morinaga, S., & Demura, S. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02712-6 · Cited by 6
Babatunde, O. O., Membribes, S. C., Anthonescu, C., Bradić, M., O’Malley, B., Linkov, I., Bartlett, E. K., Momtaz, P., Alektiar, K. M., Gounder, M. M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00878-w · Cited by 3
Self-citationZhuang, A., Xiao, Z., Chengfei, X., Zhe, X., Chen, Y., Chenhe, Z., Xie, F., Fan, Y., Mengmeng, X., Ye, F., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04007-1 · Cited by 3
Metadata
- Authors
- Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., Tap, W. D., Schwartz, G. K., George, S., & D'Angelo, S. P.
- Affiliations
- University of Florida (US)
- The Ohio State University (US)
- Mayo Clinic (US)
- Washington University in Saint Louis, Saint Louis, Missouri, USA
- Memorial Sloan Kettering Cancer Center (US)
- University of Iowa (US)
- National Institutes of Health (US)
- Case Western Reserve University (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center, New York, New York, USA
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2024-09
- Volume
- 12
- Issue
- 9
- Pages
- e009472
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC11440204
- OpenAlex
- W4402951295
- Semantic Scholar
- 32359da5182841afb2371076d8a2c149386f8fe4
- Cited by
- 21
- References
- 54
- Citations by year
- 2026: 11 · 2025: 10
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cycle for Survival (n/a)
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology (n/a)
- National Cancer Institute of the National Institutes of Health (P30CA08748, U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233290, UG1CA233331, UG1CA233339)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- nivolumab, ipilimumab, metastatic sarcoma, immune checkpoint inhibitors, combination immunotherapy, gastrointestinal stromal tumor, malignant fibrous histiocytoma, dedifferentiated liposarcoma, predictive biomarkers, genomic instability, gene fusion, subclonal mutations, treatment-related adverse events
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Sarcoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. https://app.cochat.ai/papers/10.1136/jitc-2024-009472
- The paper
- Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., Tap, W. D., Schwartz, G. K., George, S., & D'Angelo, S. P. (2024). A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.